



May 10, 2024

✓ **BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
MUMBAI - 400 001

**National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
MUMBAI - 400 051

**Dear Sir/Madam,**

**Re: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Subject: Re-launch of Mirabegron Extended-Release (ER) Tablets 25 mg in the United States.**

We would like to notify you that the US Court has lifted the Temporary Restraining Order and denied Astellas' request for a preliminary injunction on Mirabegron ER Tablets. Thereafter, shipment of the product has now resumed.

Mirabegron ER Tablets, 25 mg are a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc., and were launched by Lupin in April 2024.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**